Trial
NCT01357655
Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Bristol-Myers Squibb
Collaborators
—
Condition
Leukemia
Intervention
Dasatinib
Why stopped
No participants enrolled in this trial could receive the SMO antagonist as a recommended phase 2 dose was not determined by a different, concurrently-run trial.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-03-14